Related Experiment Videos

Anesthesia with increasing doses of sufentanil and midlatency auditory evoked potentials in humans

D Schwender1, E Weninger, M Daunderer

  • 1Institute for Anesthesiology, University of Munich, Germany.

Insights

Sufentanil

Area of Science:

  • Anesthesiology
  • Neuroscience
  • Pharmacology

Background:

  • Opioid analgesics like sufentanil are commonly used in anesthesia.
  • Understanding their effects on brain activity, specifically auditory evoked potentials, is crucial for patient safety.
  • Previous research has compared fentanyl, alfentanil, and morphine, but sufentanil's specific impact on midlatency auditory evoked potentials (MLAEP) requires clarification.

Purpose of the Study:

  • To investigate the effects of increasing sufentanil doses on midlatency auditory evoked potentials (MLAEP).
  • To compare sufentanil's impact on MLAEP with known effects of alfentanil, fentanyl, and morphine.
  • To assess dose-dependent changes in MLAEP parameters during general anesthesia.

Main Methods:

  • 16 patients undergoing major urologic surgery received incremental doses of sufentanil during general anesthesia.
  • Midlatency auditory evoked potentials (MLAEP) were recorded in awake patients and after each sufentanil dose.
  • Measurements included latencies and amplitudes of specific MLAEP peaks (V, Na, Pa, Nb, P1).

Main Results:

  • The brainstem response (peak V) remained stable with increasing sufentanil doses.
  • Significant increases in latency and decreases in amplitude were observed for later MLAEP components (Nb, P1) after low sufentanil doses (1-2 µg/kg).
  • Early cortical potentials (Na, Pa) showed minimal latency increases, with amplitudes largely unaffected, returning to awake patterns at higher doses.

Conclusions:

  • Sufentanil's effects on MLAEP are primarily on later components, with early cortical potentials showing relative stability.
  • These findings suggest sufentanil does not significantly differ from other potent opioids like alfentanil, fentanyl, and morphine in its impact on MLAEP.
  • Sufentanil can be safely administered within the studied dosage range without substantial disruption of MLAEP.

Related Concept Videos